Buy Mankind Pharma; target of Rs 3050: Motilal Oswal
Motilal Oswal is bullish on Mankind Pharma has recommended buy rating on the stock with a target price of Rs 3050 in its ...
Hosted on MSN3mon
Mankind Pharma completes acquisition of BSV for Rs 13,768 crore
MD and CEO, BSV. Mankind Pharma and its wholly-owned subsidiary (WOS) acquired 100 per cent stake in BSV, with the transaction funded through a combination of internal accruals and external debt.
Hosted on MSN3mon
Mankind Pharma Acquires Bharat Serums and Vaccines for INR 13,768 Cr
Mankind Pharma has successfully completed its acquisition ... Sanjiv Navangul, MD and CEO of BSV, echoed this sentiment, highlighting that joining Mankind will make BSV "bigger, stronger, and ...
India's Mankind Pharma misses Q3 profit view as expenses jump
India's Mankind Pharma reported a smaller-than-expected third-quarter profit on Thursday, hurt by a sharp rise in expenses.
Mankind Pharma shares fall 4% as Macquarie downgrades to 'underperform'
Macquarie has lowered its FY25/26/27 earnings estimates by 17 percent, 24 percent, and 17 percent, respectively, due to ...
The Financial Express7d
Q3FY25: Mankind Pharma’s revenue up by 24 percent to Rs 3,230 Crore; Profit at Rs 380 crore
Pharma major Mankind Pharma on Thursday reported its financial results for the third quarter and nine months ended 31 st December 2024. The company reported revenue from Operations at Rs.